F-045
SURVIVAL PROGNOSIS OF PULMONARY METASTASECTOMY FOR COLORECTAL CANCER HAS BEEN IMPROVED WITH COMBINATION OF NEW CHEMOTHERAPY

Recently new chemotherapy, i.e. FOLFOX or FOLFIRI with bevacizumab improved prognosis of patients with unresectable or recurrent colorectal cancer. We examined prognostic impact of these regimens on the patients who had undergone pulmonary metastasectomy of colorectal cancer.

We conducted a retrospective multicentre study: 1229 eligible patients undergoing pulmonary metastasectomy for curative intent were enrolled from 27 hospitals. According to regimens of chemotherapy for recurrent colorectal cancer, these patients were divided into 3 groups. Group A, B, and C included patients undergoing metastasectomy between 1982 and 1999 (n = 580), between 2000 and 2004 (n = 423), and between 2005 and 2007 (n = 226), respectively. FOLFOX or FOLFIRI was adapted to patients in Group C. Clinical factors affecting postoperative survival time were analyzed.

The 5-year cumulative survival rates after metastasectomy were 50% in Group A, 56% in Group B, and 63% in Group C (P < 0.0001). Chemotherapy was performed on 142 patients in Group A, 88 patients in Group B, and 62 patients in Group C. The 5-year survival rates after both metastasectomy and chemotherapy were significantly higher in Group C patients; 28% in Group A, 47% in Group B, and 54% in Group C (P < 0.0001). However, postoperative prognosis of the patients without chemotherapy showed no significant difference among the groups. In Group C, patients who had chemotherapy showed significantly higer survival rate than those who did not undergo chemotherapy by multivariate analysis. However, in Group A and B, patients did not benefit from chemotherapy.

The more recent the period of surgery, the higher the survival rates of patients after pulmonary metastasectomy of colorectal cancer, if the patients underwent chemotherapy. It implies that newer chemotherapy regimens had positive impact on patients who had undergone pulmonary metastasectomy of colorectal cancer.

All authors have declared no conflicts of interest.